Biotech · Private company
Palladio Biosciences
Track this companyFree. Adds Palladio Biosciences to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- LixivaptanPhase 3 · Autosomal Dominant Polycystic KidneyClinicalTrials.gov · fetched Nov 12, 2026
- LixivaptanPhase 3 · Polycystic Kidney Disease, AdultClinicalTrials.gov · fetched Nov 12, 2026
- LixivaptanPhase 2 · Autosomal Dominant Polycystic Kidney DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- LixivaptanPolycystic KidneyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303PHASE3 · TERMINATED · started Feb 10, 2022ClinicalTrials.gov NCT05208866 · fetched Nov 12, 2026
- Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney DiseasePHASE3 · TERMINATED · started Oct 28, 2021ClinicalTrials.gov NCT04064346 · fetched Nov 12, 2026
- Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney DiseasePHASE3 · TERMINATED · started Sep 2, 2020ClinicalTrials.gov NCT04152837 · fetched Nov 12, 2026
- The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney DiseasePHASE2 · COMPLETED · started Sep 14, 2018ClinicalTrials.gov NCT03487913 · fetched Nov 12, 2026
- Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney DiseaseNO_LONGER_AVAILABLEClinicalTrials.gov NCT03717181 · fetched Nov 12, 2026